NFE2L2 and central nervous system cancer: Additionally, the decrease in Nrf2 and phosphorylated VEGFR2 and the increase in Keap1 in Apatinib-challenged glioma cells were abolished by the Nrf2 overexpression (Figures 5(g) and 5(h)).